Key Takeaways
- England’s health technology assessment body, NICE, is listening to feedback from different stakeholders, including health economists, on how its severity modifier is applied to give certain drugs a higher value rating in assessments.
- During the NICE annual conference, health economists were at odds over whether NICE’s thresholds should be adjusted for certain medicines, and the societal implications of any changes.
- Industry maintained its long-standing position that NICE’s severity modifier should be adjusted to allow drugs that treat less severe conditions to have a higher weighting.
It is “ridiculous” that England’s health technology assessment (HTA) agency, NICE, uses a single threshold for the cost-effectiveness of most medicines to decide whether they can be funded through the...
“I have a love-hate relationship with cost-effectiveness thresholds. I kind of love thinking about them and writing about them and hopefully talking about them today, but I also hate them,”...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?